Table 3.
Selected predictor variables stratified by SARS-CoV-2 vaccine hesitancy.
| Variable | Total(n=11,584) | SARS-CoV-2 vaccine |
P value | ||
|---|---|---|---|---|---|
| Not hesitant 8691 (75•0%) | Hesitant 2696 (23•3%) | Missing 199 (1•7%) | |||
| TRUST VARIABLES | |||||
|
Belief in COVID-19 ‘conspiracies’ score, med (IQR) (min 6 [does not believe] - max 24 [strongly believes]) |
9 (8 - 10) | 8 (7 - 10) | 10 (8 - 11) | 10 (9 - 13) | <0·0001* |
|
Pro-vaccine score, med (IQR) (min 4 [anti-vaccination] - max 20 [pro-vaccination]) |
16 (14 - 17) | 16 (14 - 17) | 14 (12 - 16) | 13 (11 - 16) | <0·0001* |
| Influenza vaccination status 2019 - 2020, n(%) | |||||
| Vaccinated | 8279 (71·9%) | 6569 (76·0%) | 1605 (59·9%) | 105 (54·1%) | <0·0001* |
| Unvaccinated | 3233 (28·1%) | 2070 (24·0%) | 1074 (40·1%) | 89 (45·9%) | |
| Trust in employer to address a concern about unsafe clinical practice, n(%) | |||||
| 1 (does not trust employer) | 356 (3·3%) | 252 (3·1%) | 95 (3·8%) | 9 (5·1%) | <0·0001† |
| 2 | 950 (8·9%) | 649 (8·1%) | 289 (11·6%) | 12 (6·8%) | |
| 3 | 1807 (16·9%) | 1241 (15·4%) | 532 (21·3%) | 34 (19·2%) | |
| 4 | 4113 (38·4%) | 3113 (38·7%) | 942 (37·8%) | 58 (32·8%) | |
| 5 (trusts employer) | 3481 (32·5%) | 2781 (34·6%) | 636 (25·5%) | 64 (36·2%) | |
| Discrimination at work on the basis of ethnicity, nationality or religion, n(%) | |||||
| Has not experienced discrimination | 9270 (86·6%) | 7072 (87·9%) | 2063 (83·1%) | 135 (78·5%) | <0·0001* |
| Has experienced discrimination | 1434 (13·4%) | 977 (12·1%) | 420 (16·9%) | 37 (21·5%) | |
| RISK VARIABLES | |||||
| Previous laboratory evidence of COVID-19 (PCR or serology), n(%) | |||||
| Never tested | 1903 (16·5%) | 1449 (16·6%) | 420 (15·6%) | 34 (17·4%) | <0·0001* |
| Tested negative | 7350 (63·5%) | 5635 (64·9%) | 1610 (59·8%) | 105 (53·6%) | |
| Tested positive | 2316 (20·0%) | 1597 (18·4%) | 662 (24·6%) | 57 (29·1%) | |
| Number of comorbidities, n(%) | |||||
| 0 | 7841 (70·7%) | 5801 (69·6%) | 1910 (74·1%) | 130 (73·5%) | <0·0001* |
| 1 | 2528 (22·8%) | 1956 (23·5%) | 532 (20·6%) | 40 (22·6%) | |
| ≥2 | 724 (6·5%) | 580 (7·0%) | 137 (5·3%) | 7 (4·0%) | |
| Pregnancy, n(%) | |||||
| Not pregnant | 10,948 (98·7%) | 8286 (99·4%) | 2490 (96·7%) | 194 (97·5%) | <0·0001* |
| Pregnant | 141 (1·3%) | 50 (0·6%) | 86 (3·3%) | 5 (2·5%) | |
| Perceived risk of hospitalisation with COVID-19, med, (IQR) | |||||
| (100 point scale) | 20 (5 - 50) | 20 (5 - 50) | 20 (5 - 40) | 15 (3 - 50) | 0·0004† |
| Concerned about unknowingly spreading COVID-19, n(%) | |||||
| Not concerned | 5745 (49·8%) | 4285 (49·5%) | 1362 (50·8%) | 98 (50·8%) | 0·2* |
| Concerned | 5781 (50·2%) | 4367 (50·5%) | 1319 (49·2%) | 95 (49·2%) | |
| Exposed to COVID-19 patients at work, n(%) | |||||
| Unexposed | 7164 (66·1%) | 5476 (67·3%) | 1589 (62·9%) | 99 (55·3%) | <0·0001* |
| Exposed | 3682 (34·0%) | 2663 (32·7%) | 939 (37·1%) | 80 (44·7%) | |
⁎
chi-square,
†
Wilcoxon rank-sum for comparison between hesitant and non-hesitant cohorts.
For categorical variables, percentages are column wise apart from totals which are computed row wise.
For details of the derivation of the trust variables please see supplementary information. Comorbidities Include: organ transplant, diabetes, heart disease, hypertension, stroke, kidney disease, liver disease, anaemia, asthma, lung disease, cancer, neurological disorder and immunosuppression